Evogene Ltd. (TASE: EVGN) announced today
that it has received $9 million from the exercise of the company's series 1
options (expiration date May 31, 2009). The options were issued in June
2007 as part of the company's initial public offering on the Tel Aviv Stock
Exchange.

Ofer Haviv, Evogene's president and CEO, stated: "We welcome this vote of
confidence of our investors in the company with the exercise of 99.6% of
the issued series 1 options."

About Evogene

Evogene is a world leading developer of improved plant traits. The
company's proprietary product development platform combines state of the
art computational gene discovery technology (The 'ATHLETE'), plant and
field validation capabilities and unique selection systems. Evogene's
current programs focus on the improvement of key plant traits, such as
yield and stress tolerance, and the improvement of plants specifically for
biofuel uses. Evogene has collaboration and licensing agreements with world
leading companies in the agro-biotech and alternative energy industries.
Evogene's headquarters are in Rehovot, Israel, and its stock is traded on
the Tel Aviv Stock Exchange (TASE: EVGN). For additional information,
please visit Evogene's website at www.evogene.com.

This press release contains "forward-looking statements." These statements
include words like "may," "expects," "believes," "scheduled" and "intends,"
and they describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that may cause
the actual results, performance or achievements of Evogene Ltd. to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements.